Literature DB >> 31884700

Limitations of 6-minute walk test reference values for spinal muscular atrophy.

Ashley M Goodwin1,2, Kayla M D Cornett3, Marnee J McKay4, Joshua Burns4, Carol Ewing Garber2, Darryl C De Vivo3, Jacqueline Montes1,3.   

Abstract

INTRODUCTION: The 6-minute walk test (6MWT) is a well-established clinical assessment of functional endurance, validated as a measure of walking ability in spinal muscular atrophy (SMA). The current availability of disease-modifying therapies for SMA indicates a growing need for normative reference data to compare SMA patients with healthy controls.
METHODS: The literature was searched in two scientific databases. Studies were evaluated and selected based on adherence to American Thoracic Society guidelines for administering the 6MWT. Reference equations from the selected studies were applied to 6MWT data collected from SMA patients to calculate and compare % predicted values.
RESULTS: Three pediatric and six adult studies were selected for comparison. The % predicted values using the pediatric and adult equations ranged from 47.7 ± 18.2% to 67.6 ± 26.2% and 43.0 ± 17.9% to 59.5 ± 26.2%, respectively, and were significantly different (P < 0.001). DISCUSSION: Results suggest significant variability between % predicted values derived from published reference equations in children and adults, despite adherence to 6MWT standardization.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  6-minute walk test; neuromuscular disease; normative reference; outcome measure; spinal muscular atrophy

Mesh:

Year:  2020        PMID: 31884700      PMCID: PMC7024648          DOI: 10.1002/mus.26794

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  34 in total

Review 1.  Reference values for standardized tests of walking speed and distance: a systematic review.

Authors:  Nancy M Salbach; Kelly K O'Brien; Dina Brooks; Emma Irvin; Rosemary Martino; Pam Takhar; Sylvia Chan; Jo-Anne Howe
Journal:  Gait Posture       Date:  2014-10-12       Impact factor: 2.840

Review 2.  Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy.

Authors:  David R Corey
Journal:  Nat Neurosci       Date:  2017-02-13       Impact factor: 24.884

3.  Functional exercise capacity evaluated by timed walk tests in myasthenia gravis.

Authors:  Yeliz Salci; Ecem Karanfil; Ayla Fil Balkan; Ebru Çalik Kütükçü; Ali Naim Ceren; Fatma Ayvat; Can Ebru Bekircan-Kurt; Kadriye Armutlu
Journal:  Muscle Nerve       Date:  2018-10-17       Impact factor: 3.217

4.  Reference values for developing responsive functional outcome measures across the lifespan.

Authors:  Marnee J McKay; Jennifer N Baldwin; Paulo Ferreira; Milena Simic; Natalie Vanicek; Joshua Burns
Journal:  Neurology       Date:  2017-03-22       Impact factor: 9.910

5.  Six-minute walk test in healthy children: is the leg length important?

Authors:  Andréia C Oliveira; Camila C Rodrigues; Denise S Rolim; Altay A L Souza; Oliver A Nascimento; José R Jardim; Tatiana Rozov
Journal:  Pediatr Pulmonol       Date:  2012-11-20

6.  Clinical features of late-onset Pompe disease: a prospective cohort study.

Authors:  John H J Wokke; Diana M Escolar; Alan Pestronk; Kenneth M Jaffe; Gregory T Carter; Leonard H van den Berg; Julaine M Florence; Jill Mayhew; Alison Skrinar; Deyanira Corzo; Pascal Laforet
Journal:  Muscle Nerve       Date:  2008-10       Impact factor: 3.217

Review 7.  "The Times They Are a-Changin'." In reply to El-Zaidy et al.: AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort.

Authors:  Laurent Servais
Journal:  J Neuromuscul Dis       Date:  2019

8.  Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study.

Authors:  Darryl C De Vivo; Enrico Bertini; Kathryn J Swoboda; Wuh-Liang Hwu; Thomas O Crawford; Richard S Finkel; Janbernd Kirschner; Nancy L Kuntz; Julie A Parsons; Monique M Ryan; Russell J Butterfield; Haluk Topaloglu; Tawfeg Ben-Omran; Valeria A Sansone; Yuh-Jyh Jong; Francy Shu; John F Staropoli; Douglas Kerr; Alfred W Sandrock; Christopher Stebbins; Marco Petrillo; Gabriel Braley; Kristina Johnson; Richard Foster; Sarah Gheuens; Ishir Bhan; Sandra P Reyna; Stephanie Fradette; Wildon Farwell
Journal:  Neuromuscul Disord       Date:  2019-09-12       Impact factor: 4.296

9.  Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy.

Authors:  Jacqueline Montes; Sally Dunaway Young; Elena S Mazzone; Amy Pasternak; Allan M Glanzman; Richard S Finkel; Basil T Darras; Francesco Muntoni; Eugenio Mercuri; Darryl C De Vivo; Kathie M Bishop; Eugene Schneider; C Frank Bennett; Richard Foster; Wildon Farwell
Journal:  Muscle Nerve       Date:  2019-07-27       Impact factor: 3.852

10.  Reference equations for 6-min walk test in healthy Indian subjects (25-80 years).

Authors:  Ramanathan Palaniappan Ramanathan; Baskaran Chandrasekaran
Journal:  Lung India       Date:  2014-01
View more
  2 in total

1.  Natural history of 10-meter walk/run test performance in spinal muscular atrophy: A longitudinal analysis.

Authors:  Kristin J Krosschell; Elise L Townsend; Michael Kiefer; Sarah D Simeone; Katelyn Zumpf; Leah Welty; Kathryn J Swoboda
Journal:  Neuromuscul Disord       Date:  2021-08-24       Impact factor: 4.296

2.  Nusinersen in pediatric and adult patients with type III spinal muscular atrophy.

Authors:  Maria Carmela Pera; Giorgia Coratti; Francesca Bovis; Marika Pane; Amy Pasternak; Jacqueline Montes; Valeria A Sansone; Sally Dunaway Young; Tina Duong; Sonia Messina; Irene Mizzoni; Adele D'Amico; Matthew Civitello; Allan M Glanzman; Claudio Bruno; Francesca Salmin; Simone Morando; Roberto De Sanctis; Maria Sframeli; Laura Antonaci; Anna Lia Frongia; Annemarie Rohwer; Mariacristina Scoto; Darryl C De Vivo; Basil T Darras; John Day; William Martens; Katia A Patanella; Enrico Bertini; Francesco Muntoni; Richard Finkel; Eugenio Mercuri
Journal:  Ann Clin Transl Neurol       Date:  2021-06-24       Impact factor: 4.511

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.